Iconic Therapeutics

		More >>
Welcome To Iconic Therapeutics Iconic Therapeutics, Inc., an Atlanta, Georgia based biopharmaceutical company, has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1™. hI-con1 binds tissue factor More »
Molecular Structure	Statistical Analysis		PHASE 1 STUDY Iconic recently completed a prospective, multi-center study evaluating the safety and tolerability of a single, intravitreous injection of 60µg, 150µg and 300µg of hI-con1 alone or with anti-VEGF therapy in 18 patients (6 per dosing cohort) with wet AMD. The 1st, 2nd and 3rd patient in each dose cohort were end-stage/salvage eyes (n=9); the 4th, 5th and 6th patient in each dose cohort had no more than three prior anti-VEGF injection and included treatment naïve eyes (n=9). All patients were followed for six months. No dose limiting toxicities were observed. Evidence of dose-related biologic activity with reduced OCT thickness, evidence of CNV regression, and gains in BCVA were observed in many of the treated eyes. Further studies are planned. More »

Welcome To Iconic Therapeutics

Iconic Therapeutics, Inc., an Atlanta, Georgia based biopharmaceutical company, has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1™. hI-con1 binds tissue factor More »

Molecular Structure

Statistical Analysis

PHASE 1 STUDY

Iconic recently completed a prospective, multi-center study evaluating the safety and tolerability of a single, intravitreous injection of 60µg, 150µg and 300µg of hI-con1 alone or with anti-VEGF therapy in 18 patients (6 per dosing cohort) with wet AMD. The 1st, 2nd and 3rd patient in each dose cohort were end-stage/salvage eyes (n=9); the 4th, 5th and 6th patient in each dose cohort had no more than three prior anti-VEGF injection and included treatment naïve eyes (n=9). All patients were followed for six months. No dose limiting toxicities were observed. Evidence of dose-related biologic activity with reduced OCT thickness, evidence of CNV regression, and gains in BCVA were observed in many of the treated eyes. Further studies are planned. More »